1. Home
  2. NCA vs DCTH Comparison

NCA vs DCTH Comparison

Compare NCA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California Municipal Value Fund

NCA

Nuveen California Municipal Value Fund

HOLD

Current Price

$9.02

Market Cap

294.3M

Sector

Finance

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.91

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCA
DCTH
Founded
1987
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
294.3M
350.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCA
DCTH
Price
$9.02
$9.91
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$22.60
AVG Volume (30 Days)
59.6K
484.9K
Earning Date
01-01-0001
11-04-2025
Dividend Yield
3.92%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
$79,603,000.00
Revenue This Year
N/A
$131.69
Revenue Next Year
N/A
$39.22
P/E Ratio
N/A
$288.36
Revenue Growth
N/A
251.54
52 Week Low
$7.77
$8.12
52 Week High
$9.12
$18.23

Technical Indicators

Market Signals
Indicator
NCA
DCTH
Relative Strength Index (RSI) 59.89 50.27
Support Level $8.74 $9.98
Resistance Level $8.92 $10.37
Average True Range (ATR) 0.10 0.35
MACD 0.03 -0.02
Stochastic Oscillator 85.29 24.48

Price Performance

Historical Comparison
NCA
DCTH

About NCA Nuveen California Municipal Value Fund

Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: